3 results
Approved WMOWill not start
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
Approved WMOCompleted
Primary Objective: To assess the level of agreement between ACC variables (amplitude, latency) in CI users and the FDT perceived by the same CI users.Secondary Objectives: • To assess correlations between speech perception and ACC variables, and…
Approved WMOCompleted
To determine the safety and tolerability of L19-IL2 combined with SABR.